Affimed NV (STU:A28A)
€ 1.1 -0.045 (-3.93%) Market Cap: 18.70 Mil Enterprise Value: 6.65 Mil PE Ratio: 0 PB Ratio: 1.07 GF Score: 30/100

Affimed NV Corporate Call Transcript

Jun 03, 2023 / 11:00AM GMT
Operator

Good day, everyone, and welcome to Affimed's AFM24 Update Call. (Operator Instructions)

I would now like to introduce your host for day's call, Alex Fudukidis, Head of Investor Relations at Affimed. Please go ahead.

Alexander Fudukidis
Affimed N.V. - Head of IR & Director of IR

Thank you, Kevin, and thank you all for joining us for today's call to discuss the findings from the poster presentation of our AFM24 monotherapy study in non-small cell lung cancer that was presented earlier today by Dr. Anthony El-Khoueiry, Associate Director of Clinical Research at USC Norris Comprehensive Cancer Center and Principal Investigator of the AFM24 studies.

Before we begin, I'd like to remind everyone that we issued a press release earlier today and have since added the presentation that we will be using on this call, both of which can be found on the Investor Relations section of our website. On the call today, we have members of our management team, including Dr. Adi Hoess, our Chief Executive Officer; Dr. Andreas Harstrick, our Chief Medical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot